A comparison between the fluocinolone acetonide (Retisert) and dexamethasone (Ozurdex) intravitreal implants in uveitis

Journal of Ocular Pharmacology and Therapeutics

Volumn 29, Issue 5, 2013, Pages 501-507

  Arcinue, Cheryl A ^a,b   Cerón, Olga M ^a,b   Foster, C Stephen ^a,b,c  

^a MASSACHUSETTS EYE RESEARCH AND SURGERY INSTITUTION   (United States)

^b Massachusetts Eye Research and Surgery Institute   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DEXAMETHASONE; FLUOCINOLONE ACETONIDE;

ADULT; ARTICLE; CATARACT; CLINICAL ARTICLE; COMPARATIVE EFFECTIVENESS; DRUG EFFICACY; FEMALE; FOLLOW UP; GLAUCOMA; HUMAN; INTRAVITREAL IMPLANT; MALE; RECURRENCE RISK; RETROSPECTIVE STUDY; SURVIVAL TIME; UVEITIS; VISUAL ACUITY;

ADULT; AGED; ANTI-INFLAMMATORY AGENTS; CATARACT; DEXAMETHASONE; DISEASE PROGRESSION; DRUG IMPLANTS; FEMALE; FLUOCINOLONE ACETONIDE; FOLLOW-UP STUDIES; GLUCOCORTICOIDS; HUMANS; INTRAVITREAL INJECTIONS; MALE; MIDDLE AGED; RECURRENCE; RETROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME; UVEITIS; VISUAL ACUITY;

EID: 84876276456     PISSN: 10807683     EISSN: 15577732     Source Type: Journal    
DOI: 10.1089/jop.2012.0180     Document Type: Article

References (13)

1. Durrani, O.M., Meads, C.A., and Murray, P.I. Uveitis: a potentially blinding disease. Ophthalmologica 218:223-236, 2004. (Pubitemid 38969828)
2. Taban, M., Lowder, C.Y., and Kaiser, P.K. Outcome of flu-ocinolone acetonide implant (Retisert) reimplantation for chronic noninfectious posterior uveitis. Retina 28:1280-1288, 2008.
3. Jaffe, G.J., Martin, D., Callanan, D., et al. Fluocinolone acetonide implant (Retisert) for noninfectious posterior uveitis: thirty-four week results of a multicenter randomized clinical study. Ophthalmology 113:1020-1027, 2006. (Pubitemid 43795240)
4. Jaffe, G.J., Yang, C.H., Guo, H., et al. Safety and pharma-cokinetics of an intraocular fluocinolone acetonide sustained delivery device. Invest. Ophthalmol. Vis. Sci. 41:3569-3575, 2000.
5. Driot, J.Y., Novack, G.D., Rittenshouse, K.D., et al. Ocular pharmacokinetics of fluocinolone acetonide after Retisert intravitreal implanation in rabbits over a 1-year period. J. Ocul. Pharmacol. Ther. 20:269-275, 2004. (Pubitemid 38849806)
6. Callanan, D.G., Jaffe, G.J., Martin, D.F., et al. Treatment of posterior uveitis with a fluocinolone acetonide implant: 3-year clinical trial results. Arch. Ophthalmol. 126:1191-1201, 2008.
7. Pavesio, C., Zierhut, M., Bairi, K., et al. Evaluation of an intravitreal fluocinolone acetonide implant versus standard systemic therapy in noninfectious posterior uveitis. Ophthalmology 117:567-575, 2010.
8. London NJS, Chiang, A., and Haller, J.A. The dexametha-sone drug delivery system: indications and evidence. Adv. Ther. 28:351-366, 2011.
9. Williams, G.A., Haller, J.A., Kuppermann, B.D., et al. Dex-amethasone posterior-segment drug delivery system in the treatment of macular edema resulting from uveitis or Irvine-Gass syndrome. Am. J. Ophthalmol. 147:1048-1054, 2009.
10. Lowder, C., Belfort Jr., R., Lightman, S., et al. Dex-amethasone intravitreal implant for noninfectious intermediate or posterior uveitis. Arch. Ophthalmol. 129:545-553, 2011.
11. Pardo-López, D., Francés-Muñoz, E., Gallego-Pinazo, R., et al. Anterior chamber migration of dexamethasone in-travitreal implant (Ozurdex). Graefes Arch. Clin. Exp. Oph-thalmol. 2011. http://dx.doi.org/10. 1007/s00417-011-1802-x.
12. Bansal, R., Bansal, P., Kulkarni, P., et al. Wandering Ozurdex implant. J. Ophthal. Inflamm. Infect. 2:1-5, 2012.
13. Ruiz-Moreno, J.M., Montero, J.A., Artola, A., and Barile, S. Anterior chamber transit of triamcinolone after intravitreal injection. Arch. Ophthalmol. 123:129-130, 2005. (Pubitemid 40105453)